Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections

Area of Science:

• Public Health
• Infectious Diseases
• Clinical Pharmacology

Background:

• Bacterial sexually transmitted infections (STIs) are increasing among men who have sex with men.
• Shifting attitudes towards human immunodeficiency virus (HIV) infection due to effective treatments and prevention strategies have led to increased sexual contact and decreased condom use.
• Doxycycline is a known primary prophylaxis agent for various infectious diseases.

Purpose of the Study:

• To review the current research on doxycycline prophylaxis for preventing syphilis and other bacterial STIs.
• To identify knowledge gaps and challenges associated with its use.
• To inform future research and clinical practice.

Main Methods:

• A state-of-the-art review was conducted by international experts.
• Focused literature searches supplemented the initial inquiry.
• Analysis included two small, short-term randomized controlled trials and ongoing/developing clinical studies.

Main Results:

• Two small randomized controlled trials demonstrated high efficacy for doxycycline prophylaxis in preventing bacterial STIs.
• Five additional clinical studies are in progress or development, with varied designs and populations.
• Doxycycline prophylaxis for bacterial STIs appears promising based on initial findings.

Conclusions:

• Doxycycline prophylaxis demonstrates potential for preventing bacterial STIs, particularly in high-risk populations.
• Further robust data are required regarding efficacy, optimal dosing, long-term safety, community acceptance, and cost-effectiveness.
• Addressing antimicrobial resistance and behavioral risk compensation is crucial for successful implementation.